�Nine of the nation's leading scientific research institutions have launched a new partnership to boost Australia's research capacity for tackling major wellness problems including cancer, diabetes, deafness, sterility, autoimmune disease and arthritis.
The Australian Phenomics Network (APN) is providing Australian and International researchers with the latest infrastructure for the study of human disease. The alliance brings together facilities, equipment and expertise to accelerate progress in the supplying of biological models for medical enquiry. This facilitates Australia making genuine inroads against all kinds of diseases.
"This is incredibly exciting science - frontier scientific discipline - and it's great to see Australian researchers leading the way," aforementioned Senator Kim Carr, Minister for Innovation, Industry, Science and Research.
APN Chief Scientific Officer Professor Chris Goodnow said: "Together we'll be able to access biological models that have been developed for specific inquiry projects. Combining our technological resources agency we can buoy spend more than time actually doing the research that will make a real difference in our efforts to combat diseases."
APN Convenor Associate Professor Moira O'Bryan from Monash University said the project is around combining efforts and load-bearing all Australian researchers. "Australia has a wealth of talent in medical research, spread across a number of institutions. Each governing body has its own strengths in dissimilar areas," she says. "The APN will allow our resources to be combined and greatly enhance Australia's research capacity."
The APN is also working with the Atlas of Living Australia project to develop a framework for building web resources that capture, gloss and circularize research data and will enable research outcomes to be translated to clinical outcomes more rapidly.
The APN is funded by the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS), contributions from state governments, and the National Health and Medical Research Council (NHMRC).
The mesh combines the resources of the Australian National University, Monash University, the Walter and Eliza Hall Institute for Medical Research, the University of Melbourne, Queensland Institute of Medical Research, the Institute of Medical and Veterinary Science, the Centenary Institute of Cancer Medicine and Cell Biology, Menzies Research Institute and the Animal Resource Centre.
The APN's expertness is complemented by national and outside partnerships with the Garvan Institute, the Institute of Molecular Bioscience, the National Institutes of Health (USA), the Wellcome Trust (UK) and the University of Manitoba (Canada).
Source: Simon Couper
Research Australia
More info
Sunday 24 August 2008
Thursday 14 August 2008
Fbn Takes Battle With Cnbc Onto Its Turf
The entrant Fox Business Network is taking its battle against the entrenched business channel CNBC to CNBC itself. In a kind of Trojan cavalry maneuver, the News Corp-owned channel is buying time on "station breaks" -- the sentence that CNBC allots to cable providers to sell to local advertisers -- to hammer CNBC for dropping commercial enterprise news reports between 5 00 p.m. and 8 00 p.m. during the Olympics in order to cover second-tier events at the Olympics. During commercials airing in major U.S. markets on Comcast and Time Warner Cable-owned systems, FBN anchor Liz Claman is seen saying, "When it comes to commercial enterprise, this city doesn't play games, and neither do you. In just a couple of minutes, CNBC is sledding to degenerate their business news scheduling. ... Switch to the Fox Business Network. ... Real patronage news and no games!"
12/08/2008
More info
Wednesday 6 August 2008
FDA Approves Expanded 510k Classification For Titan Spine's Endoskeleton(R) TA Anterior Interbody Fusion Device
�The US Food and Drug Administration (FDA) has expanded Titan Spine's ENDOSKELTON� TA Vertebral Body Replacement Device (VBR) 510k to include an Interbody Fusion Device indicant.
Under its expanded 510K indication, the Endoskeleton� TA Interbody Fusion Device is approved for use in skeletally grow patients with Degenerative Disc Disease (DDD) at 1 or two contiguous levels from L2-S1. Degenerative Disc Disease is defined as discogenic back up pain with degeneration of the phonograph record confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). Patients should cause received six months of non-operative treatment prior to treatment with the devices. The device may be used with supplemental fixing.
While degenerative disc disease is well-nigh often treated by more than conservative therapies, the condition can oft lead to more life-threatening disorders, such as lumbar spinal stricture (narrowing of the spinal canal) or spondylolistheses (disk slips onwards).
"This is an important step for Titan Spine as it gives the surgeon the ability to utilize the Endoskeleton� TA as an Interbody Device while taking off the VBR label, as comfortably as the ability to feel comfortable knowing that they now have the option to use the device in a stand-alone setting," said Steve Cichy, Vice President of Sales of Titan Spine.
Titan Spine expects that this new product indication will increase product adoption among a group of surgeons that ar focused both on proficiency proficiency and positive, predictable outcomes for their patients. Kevin Gemas, President of Titan Spine, underscored the importance of the expanded classification by adding "with an estimated 65
Under its expanded 510K indication, the Endoskeleton� TA Interbody Fusion Device is approved for use in skeletally grow patients with Degenerative Disc Disease (DDD) at 1 or two contiguous levels from L2-S1. Degenerative Disc Disease is defined as discogenic back up pain with degeneration of the phonograph record confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). Patients should cause received six months of non-operative treatment prior to treatment with the devices. The device may be used with supplemental fixing.
While degenerative disc disease is well-nigh often treated by more than conservative therapies, the condition can oft lead to more life-threatening disorders, such as lumbar spinal stricture (narrowing of the spinal canal) or spondylolistheses (disk slips onwards).
"This is an important step for Titan Spine as it gives the surgeon the ability to utilize the Endoskeleton� TA as an Interbody Device while taking off the VBR label, as comfortably as the ability to feel comfortable knowing that they now have the option to use the device in a stand-alone setting," said Steve Cichy, Vice President of Sales of Titan Spine.
Titan Spine expects that this new product indication will increase product adoption among a group of surgeons that ar focused both on proficiency proficiency and positive, predictable outcomes for their patients. Kevin Gemas, President of Titan Spine, underscored the importance of the expanded classification by adding "with an estimated 65
Subscribe to:
Posts (Atom)